NCT03575962 - A Study to Compare the Relative Bioavailability of Two Different Formulations of GSK3640254 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 18, 2018

Primary Completion Date

August 6, 2018

Study Completion Date

August 6, 2018

Conditions

HIV Infections

Interventions

DRUG

GSK3640254 bis-hydrochloride salt capsule

Administered orally (as single dose) on morning of Day 1, as 2 capsules of 100 mg following a moderate calorie and fat meal during Period 1 and Period 2, at the specified sequence, as per study.

DRUG

GSK3640254 Mesylate Salt Capsule

Administered orally (as single dose) on morning of Day 1, as 2 capsules of , 100 mg following a moderate calorie and fat meal during Period 1 and Period 2, at the specified sequence, as per study.

Trial Locations (1)

NG11 6JS

GSK Investigational Site, Nottingham